Title: Pharmacokinetic Changes in Congestive Heart Failure

Authors: Htet Htet, Saint Nway Aye, Lwin Mie Aye, Kyan Aung

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i7.71

Abstract

 Pharmacokinetic processes are recognized as “liberation, absorption (A), distribution (D), metabolism (M) and excretion (E)”. Published ADME data for each drug are usually observed on healthy individuals. It serves as an indispensable guide to prescribers. LADME guides highlight the significant role of the gastroenterology system, hepato-biliary system, cardiovascular system and renal system. Any changes in the structure and function of these systems would lead to variations in the ADME system. The existence of individual differences and pathophysiological status of major organs further affects the clinical pharmacokinetic profile of drugs. Therefore, unpredictable variations in pharmacokinetic parameters may exist in patients suffering from diseases of the heart, the liver or the kidneys. Most importantly, the deviation of pharmacokinetic parameters could affect the outcome of the management of the disease. Of these organs, the heart is a very crucial one as the circulation is the main transport route for the passage of drugs through the body. Congestive heart failure is a common cardiac disease in both the well-developed and the developing countries. The pathophysiology of congestive heart failure has already been complicated with hemodynamic abnormalities, neurohumoral mechanisms and the damage to the cardiac muscle itself. As congestive heart failure is more commonly seen in the elderly patients, age-related changes should also be considered. The objective of this article is to facilitate the better management of congestive heart failure, based on evidence-based information on pharmacokinetic changes, to make dosage adjustment of the right drug for the right patient, with minimal adverse effects. 

Keywords – clinical pharmacokinetic, congestive heart failure, pharmacokinetic changes, drug metabolism, drug absorption, drug elimination. 

References

 1.      Sica DA. Drug Absorption in the Management of Congestive Heart Failure: Loop Diuretics. Congest Heart Fail 2003 Sep-Oct; 9 (5):287-92.

2.      Shammas FV1, Dickstein K. Clinical pharmacokinetics in heart failure: An updated review. ClinPharmacokinet. 1988 Aug; 15(2):94-113.

3.      Ogawa R, Stachnik JM, Echizen, H. Clinical Pharmacokinetics of Drugs in Patients with Heart Failure. Clin Pharmacokinet 2013; 52:169–85.

4.      Carlton LD, Pollack GM, Brouwer KL. Physiologic pharmacokinetic modeling of gastrointestinal blood flow as a rate-limiting step in the oral absorption of digoxin: implications for patients with congestive heart failure receiving epopro-stenol. J Pharm Sci. 1996; 85:473–77.

5.      Berkowitz D, Droll MN, Likoff W. Malabsorption as a complication of congestive heart failure. Am J Cardiol. 1963; 11:43–47. (abstract)

6.      Benowitz NL, Meister W. Pharmacokinetics in patients with cardiac failure. ClinPharmacokinet. 1976 Nov-Dec; 1(6):389-405.

7.      Ring-Larsen H, Henriksen JH, Wilken C, Clausen J, Pals H, Christensen NJ. Diuretic treatment in decompensated cirrhosis and heart failure: effect of posture. BMJ. 1986; 292:1351–53.

8.      Flapan AD, Davies E, Waugh C, Williams BC, Shaw TR, Edwards CR. The influence of posture on the response to loop diuretics in patients with chronic cardiac failure is reduced by angiotensin converting enzyme inhibition. Eur J ClinPharmacol. 1992; 42 (6):581–86.

9.      Williams. Cardiovascular Drug Therapy in the Elderly: Theoretical and Practical Considerations. Drugs Aging 2003; 20 (6): 445-63.

10.  Sumner DJ, Russel AJ. Digoxin pharmacokinetics: multi-compartmental analysis and its implications. Br J ClinPharmacol 1976; 3: 221-29.

11.  Schwartz JB. Clinical pharmacology. In: Hazzard WR, Blass JP, Ettinger, WH Jr, et al., editors. Principles of geriatric medicine gerontology. 4th ed. New York: McGraw-Hill, 1999: 303-31. (Text book)

12.  Cockcroft D W, Gault M H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.

13.  Friedman JR, Norman DC, Yoshikawa TT. Correlation of estimated renal function parameters versus 24-hour creatinine clearance in ambulatory elderly. J Am GeriatrSoc 1989; 37:145-49.

14.  Liu. Cardiorenal syndrome in heart failure: A cardiologist’s perspective. Acute Decompensated Heart Failure. Can J Cardiol 2008 July; 24(Suppl B): 25B-29B.

15.  Greenblatt DJ, Allen MD, Shader RI. Toxicity of high-dose flurazepam in the elderly. ClinPharmacolTher 1977; 21: 355-61.

16.  Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin PharmacolTher 1997; 61(3): 331-39.

17.  Dickstein K, Till AE, Aaarsland T, Tjelta K, Abrahamsen AM, Kristianson K, Gomez HJ, Gregg H, Hichens M. The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. Br J ClinPharmacol. 1987; 23 (4):403–410.

18.  Baughman RA Jr, Arnold S, Benet LZ, Lin ET, Chatterjee K, Williams RL. Altered prazosin pharmacokinetics in congestive heart failure. Eur J ClinPharmacol. 1980; 17 (6):425–428.

19.  Crawford MH, Ludden TM, Kennedy GT. Determinants of systemic availability of hydralazine in congestive heart failure. ClinPharmacolTher. 1985; 38:538–543.

20.  Hepner GW, Vesell ES, Tantum KR. Reduced drug elimination in congestive heart failure: Studies using aminopyrine as a model drug. Am J Med. 1978 Aug; 65(2):371-376.

Corresponding Author

Dr Htet Htet

MBBS, MMedSc (Pharmacology)

Lecturer, Pathology Division, School of Medicine, International Medical University

Kuala Lumpur, Malaysia, +601123868109

Email: This email address is being protected from spambots. You need JavaScript enabled to view it., This email address is being protected from spambots. You need JavaScript enabled to view it.